

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: YU et al.

20

Docket No.: UTSD:0795

Serial No.: TBA

202

Examiner:

Filing Date: 04/30/2001

22

Art Unit:

Title: A CLASS OF 12MER PEPTIDES THAT INHIBIT THE FUNCTION OF THE MITOTIC CHECK POINT PROTEIN MAD2

2

§

§

2

cos

202

22

Box Sequence Listing

Assistant Commissioner for Patents

Washington, D.C. 20231

SEQUENCE LISTING 37 CFR 1.821

Dear Sir:

In compliance with 37 CFR 1.821, Applicants submit the attached sequence listing and provide one enclosed 3.5 inch disk. The file is stored as Seq.txt.

I hereby state that the content of the paper and computer readable copies of the sequence listing, submitted in accordance with 37 CFR 1.821(c) and (e), respectively, are the same.

Applicant believes that there is no additional fee required to file this paper. If Applicant is in error, the Commissioner is hereby authorized to charge any required fees and/or credits by this paper and during the entire pendency of this application to Account No. 06-2375/10101381.

Respectfully submitted,



Melissa W. Acosta

Registration No. 45,872

Date: April 30, 2001

FULBRIGHT & JAWORSKI L.L.P.

1301 McKinney, Suite 5100

Houston, Texas 77010-3095

(713) 651-5407 (Telephone)

(713) 651-5246 (Facsimile)

| Table 1. Demographic characteristics of the study population | |
|--|----------------|
| Age (years) | 50.0 ± 10.0 |
| Gender | |
| Male | 50.0% |
| Female | 50.0% |
| Education | |
| High school | 50.0% |
| University | 50.0% |
| Marital status | |
| Married | 50.0% |
| Single | 50.0% |
| Occupation | |
| Physician | 50.0% |
| Nurse | 50.0% |
| Other | 50.0% |
| Smoking status | |
| Smoker | 50.0% |
| Non-smoker | 50.0% |
| Alcohol consumption | |
| Alcohol consumer | 50.0% |
| Non-alcohol consumer | 50.0% |
| Family size | 3.0 ± 1.0 |
| Income (TL/month) | 1000.0 ± 500.0 |
| Health insurance | |
| Health insurance | 50.0% |
| No health insurance | 50.0% |
| Comorbidities | |
| Hypertension | 50.0% |
| Diabetes | 50.0% |
| Cholesterol | 50.0% |
| Obesity | 50.0% |
| Depression | 50.0% |
| Anxiety | 50.0% |
| Stress | 50.0% |
| Quality of life | |
| High | 50.0% |
| Low | 50.0% |
| Life satisfaction | |
| Satisfied | 50.0% |
| Dissatisfied | 50.0% |
| Health status | |
| Good | 50.0% |
| Poor | 50.0% |
| Overall health | |
| Good | 50.0% |
| Poor | 50.0% |
| Healthcare utilization | |
| Regular | 50.0% |
| Irregular | 50.0% |
| Healthcare satisfaction | |
| Satisfied | 50.0% |
| Dissatisfied | 50.0% |
| Healthcare access | |
| Easy | 50.0% |
| Difficult | 50.0% |
| Healthcare cost | |
| Low | 50.0% |
| High | 50.0% |
| Healthcare quality | |
| High | 50.0% |
| Low | 50.0% |
| Healthcare safety | |
| High | 50.0% |
| Low | 50.0% |
| Healthcare effectiveness | |
| High | 50.0% |
| Low | 50.0% |
| Healthcare equity | |
| High | 50.0% |
| Low | 50.0% |
| Healthcare sustainability | |
| High | 50.0% |
| Low | 50.0% |
| Healthcare innovation | |
| High | 50.0% |
| Low | 50.0% |
| Healthcare leadership | |
| High | 50.0% |
| Low | 50.0% |
| Healthcare collaboration | |
| High | 50.0% |
| Low | 50.0% |
| Healthcare communication | |
| High | 50.0% |
| Low | 50.0% |
| Healthcare transparency | |
| High | 50.0% |
| Low | 50.0% |
| Healthcare accountability | |
| High | 50.0% |
| Low | 50.0% |
| Healthcare integrity | |
| High | 50.0% |
| Low | 50.0% |
| Healthcare professionalism | |
| High | 50.0% |
| Low | 50.0% |
| Healthcare ethics | |
| High | 50.0% |
| Low | 50.0% |
| Healthcare justice | |
| High | 50.0% |
| Low | 50.0% |
| Healthcare freedom | |
| High | 50.0% |
| Low | 50.0% |
| Healthcare security | |
| High | 50.0% |
| Low | 50.0% |
| Healthcare stability | |
| High | 50.0% |
| Low | 50.0% |
| Healthcare resilience | |
| High | 50.0% |
| Low | 50.0% |
| Healthcare adaptability | |
| High | 50.0% |
| Low | 50.0% |
| Healthcare inclusiveness | |
| High | 50.0% |
| Low | 50.0% |
| Healthcare diversity | |
| High | 50.0% |
| Low | 50.0% |
| Healthcare innovation | |
| High | 50.0% |
| Low | 50.0% |
| Healthcare leadership | |
| High | 50.0% |
| Low | 50.0% |
| Healthcare collaboration | |
| High | 50.0% |
| Low | 50.0% |
| Healthcare communication | |
| High | 50.0% |
| Low | 50.0% |
| Healthcare transparency | |
| High | 50.0% |
| Low | 50.0% |
| Healthcare accountability | |
| High | 50.0% |
| Low | 50.0% |
| Healthcare integrity | |
| High | 50.0% |
| Low | 50.0% |
| Healthcare professionalism | |
| High | 50.0% |
| Low | 50.0% |
| Healthcare ethics | |
| High | 50.0% |
| Low | 50.0% |
| Healthcare justice | |
| High | 50.0% |
| Low | 50.0% |
| Healthcare freedom | |
| High | 50.0% |
| Low | 50.0% |
| Healthcare security | |
| High | 50.0% |
| Low | 50.0% |
| Healthcare stability | |
| High | 50.0% |
| Low | 50.0% |
| Healthcare resilience | |
| High | 50.0% |
| Low | 50.0% |
| Healthcare adaptability | |
| High | 50.0% |
| Low | 50.0% |
| Healthcare inclusiveness | |
| High | 50.0% |
| Low | 50.0% |
| Healthcare diversity | |
| High | 50.0% |
| Low | 50.0% |

<120> A CLASS OF 12MER PEPTIDES THAT INHIBIT THE FUNCTION OF THE MITOTIC CHECK
POINT PROTEIN MAD2

<140> TBA

<141> 2001-04-30

<160> 20

<170> PatentIn version 3.0

 $\langle 210 \rangle$ 1

<211> 8

<212> PRT

<213> Artificial

 $\langle 220 \rangle$

<223> Synthetic Peptide

 $\langle 220 \rangle$

<221> misc feature

$$\langle 222 \rangle \quad (6) \cdot \bar{\cdot} (6)$$

<223> X is any

<220>

<221> misc feature

$$\langle 222 \rangle \quad (1) \cdot \bar{\cdot} (8)$$

<223> Synthetic Peptide

<400> 1

Gln Trp Tyr Lys Leu Xaa Pro Pro
1 5

 $\langle 210 \rangle$ 2

<211> 12

<212> PRT

<213> Artificial Sequence

 $\langle 220 \rangle$

<221> misc ~~feature~~

$$\langle 222 \rangle \quad (1) \dots \overline{12}$$

<223> ~~synthetic~~ peptide

<400> 2

Ser Trp Tyr Ser Tyr Pro Pro Pro Gln Arg Ala Val

Ser Trp Tyr Ser Tyr Pro Pro Pro Gln Arg Ala Val
1 5 10

<210> 3
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)..(12)
<223> synthetic peptide

<400> 3

Asp Ala Arg Ile Ile Lys Leu Pro Val Pro Lys Pro
1 5 10

<210> 4
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)..(12)
<223> synthetic peptide

<400> 4

Gln Trp Leu His Phe Ala Pro Pro Pro Pro Pro Lys
1 5 10

<210> 5
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)..(12)
<223> synthetic peptide

<400> 5

Gln Trp Ile Thr Leu Ser Pro Pro Arg Ser Leu Thr
1 5 10

<210> 6
<211> 12
<212> PRT
<213> Artificial Sequence

<220>

<221> misc_feature
<222> (1)..(12)
<223> synthetic peptide

<400> 6

Ser Ala Asn Trp Thr Ile Trp Lys Pro Pro Thr Pro
1 5 10

<210> 7
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)..(12)
<223> synthetic peptide

<400> 7

Asn Trp Tyr Ser Tyr Lys Met Pro Lys His Glu Ala
1 5 10

<210> 8
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)..(12)
<223> synthetic peptide

<400> 8

Gln Trp Leu Lys Phe Ser Pro Pro Met His Ala Ser
1 5 10

<210> 9
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)..(12)
<223> synthetic peptide

<400> 9

Gly Trp Val Arg Leu Gln Pro Pro Pro Leu Ile Gln
1 5 10

25025713.1

<210> 10
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)..(12)
<223> synthetic peptide

<400> 10

Ala Trp Tyr Lys Leu Pro Lys Glu Ser Pro Leu Leu
1 5 10

<210> 11
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)..(12)
<223> synthetic peptide

<400> 11

Ser Trp Tyr His Thr Pro Ser Pro Leu Pro His Lys
1 5 10

<210> 12
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)..(12)
<223> synthetic peptide

<400> 12

Thr Trp Tyr Lys Leu Ser Asn Ser Pro Ile Tyr Gly
1 5 10

<210> 13
<211> 14
<212> PRT
<213> Homo sapiens

<400> 13

Asp Val Glu Glu Ala Lys Ile Leu Arg Leu Ser Gly Lys Pro

10

<400> 14

| | |
|-------|---------------|
| <210> | 15 |
| <211> | 14 |
| <212> | PRT |
| <213> | S. Cerevisiae |

<400> 15

| | |
|-------|----------|
| <210> | 16 |
| <211> | 14 |
| <212> | PRT |
| <213> | S. Pombe |

<400> 16

```
<210> 17
<211> 12
<212> PRT
<213> Artificial Sequence
```

```
<220>
<221> misc_feature
<222> (1)..(1)
<223> X is any
```

```
<220>
<221> misc_feature
<222> (1)..(12)
<223> Synthetic Peptide
```

```
<220>
<221> misc_feature
<222> (6)..(7)
<223> X is any
```

```
<220>
<221> misc feature
```

Express Mail No. EH244916502US

<222> (9)..(12)

<223> X is any

<400> 17

Xaa Trp Tyr Lys Leu Xaa Xaa Pro Xaa Xaa Xaa Xaa
1 5 10

<210> 18

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<221> misc_feature

<222> (4)..(5)

<223> X is any

<220>

<221> misc_feature

<222> (1)..(7)

<223> Synthetic Peptide

<400> 18

Trp Tyr Lys Leu Xaa Xaa Pro
1 5

<210> 19

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<221> misc_feature

<222> (1)..(12)

<223> Synthetic Peptide

<400> 19

Gly Trp Trp His Ile Pro Ser Pro Val Leu Arg Pro
1 5 10

<210> 20

<211> 11

<212> PRT

<213> HIV-TAT PROTEIN

<400> 20

Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg
1 5 10